Date: 2017-01-10
Type of information: Commercialisation agreement
Compound: Xadago™ (safinamide)
Company: Seqirus (Australia) Zambon (Italy)
Therapeutic area: Neurodegenerative diseases
Type agreement: commercialisation
Action mechanism: Monoamine oxidase inhibitor. Safinamide has a novel dual mechanism of action based on the enhancement of the dopaminergic function (through potent reversible inhibition of MAO-B and of dopamine uptake) and inhibition of excessive release of glutamate.
Disease: Parkinson’s disease
Details: * On January 10, 2017, Zambon and Seqirus announced that they have entered into a long term partnership covering Zambon’s Parkinson’s Disease product, Xadago® (safinamide), in Australia and New Zealand. Zambon will be responsible for product supply and Seqirus will undertake registration and commercialisation of the product. The collaboration with Zambon consolidates Seqirus’ position of being a leading in-licensing partner in the Australian and New Zealand market. Zambon has already a strategic agreeement with US WorldMeds to commercialize Xadago® in the US.
Financial terms:
Latest news:
